The Healthcare Technology Report with RJ Lumba
Welcome to The Healthcare Technology Report, a leading information source on healthcare technology companies and solutions. In this episode, we speak with Hans Keirstead, Chairman of the Board at Immunis, a clinical-stage biotechnology company developing stem cell-derived biologics to address age-related diseases and immune dysfunction. Immunis’ investigational therapy, IMM01-STEM, is a stem cell-derived secretome designed to modulate immune health and improve muscle mass and function, with initial clinical work focused on sarcopenia-related conditions. Hans is a stem cell researcher and biotech entrepreneur with prior experience developing therapies across neurology, immune disorders, and oncology. He previously served as a full professor of anatomy and neurobiology at UC Irvine and has held leadership and board roles across multiple biotechnology organizations. I am your host, RJ Lumba. We hope you enjoy the show. If you like the episode, click to follow.
44 episodes
Comments
0Be the first to comment
Sign up now and become a member of the The Healthcare Technology Report with RJ Lumba community!